Keyword: CFDA

Lilly, Chi-Med cancer drug hits phase 3 goals, eyes China NDA

Hong Kong-based Hutchison China MediTech (Chi-Med) and U.S. Big Pharma partner Eli Lilly have seen their partnered med hit its primary endpoint of increasing overall survival in certain colorectal cancer patients, as the biotech gears up for a mid-2017 filing in China.